{"prompt": "['Interferon beta-la', 'MESTRE-MS Study', 'EMR200136_59', 'medical assessment. Reasonable attempts to obtain follow-up information must be made and', 'documented.', 'Reporting of any new information on a previously reported SAE or non-serious adverse drug', 'reaction (follow-up) will follow the procedures and timelines of the original report.', '11.6', 'Regulatory Reporting to the Health Authorities', 'Expedited reporting of SAEs and non-serious adverse drug reactions to Health Authorities is', 'performed by the Sponsor local drug safety officer/Pharmacovigilance responsible at shared', 'service center according to applicable global and local requirements.', 'Serious ARs, including those associated with the comparator drug (if applicable), will be', 'expedited by the Sponsor to Health Authorities according to local regulations, which usually', 'require a maximum period of 15 days.', 'In addition, the Investigator will comply with any applicable local pharmacovigilance', 'requirements to report appropriate safety data, to national pharmacovigilance systems (e.g.', 'Yellow Card Scheme in UK), as required by country specific reporting requirements.', '12', 'Plans for Disseminating and Communicating Study Results', 'After completion of the study, the selected CRO shall prepare a final report of study results, in', 'close collaboration with the coordinating Investigator and the Sponsor.', 'All publications and presentations should be based on the final study report.', 'All information provided by the Sponsor regarding this study will be the sole property of the', 'Sponsor and must be considered as confidential. No confidential information will be disclosed to', 'third parties without the prior written consent of the Sponsor and it will be used only for', 'conducting this study.', '12.1', 'Study Report(s)', 'The completed study will be summarized in a final report that accurately and completely presents', 'the study objectives, methods, results, limitations of the study, and interpretation of the findings.', '12.2', 'Publication', 'The first publication will be a publication of the results of the analysis of the Primary Endpoint', 'that will include data from all study sites.', 'The Investigator will inform the Sponsor in advance about any plans to publish or present data', 'from the study. Any publications and presentations of the results (abstracts in journals or', 'newspapers, oral presentations, etc.), either in whole or in part, by Investigators or their', 'representatives will require pre-submission review and approval by the Sponsor.', 'CONFIDENTIAL', '42/60', 'INFORMATION', 'M']['Interferon beta-1a', 'MESTRE-MS Study', 'EMR200136_59', 'The Sponsor will not suppress or veto publications, but maintains the right to delay publication', 'in order to protect intellectual property rights.', 'CONFIDENTIAL', '43/60', 'INFORMATION', 'M']['Interferon beta-la', 'MESTRE-MS Study', 'EMR200136_597', '13', 'References', '1.', 'Calabresi PA. Diagnosis and management of multiple sclerosis. Am Fam Physician 2004;', '70: 1935-44.', '2.', 'Bergvall N, Makin C, Lahoz R, et al. Relapse rates in patients with multiple sclerosis', 'switching from interferon to fingolimod or glatiramer acetate: a US claims database study.', 'PLoS One. 2014;9(2): e88472.', '3.', 'Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in', 'multiple sclerosis. Neurology 2003;61: 1528-32.', '4.', 'Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an', 'international survey. National Multiple Sclerosis Society (USA) Advisory Committee on', 'Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46: 907-11.', '5.', 'Lugaresi A, di Ioia M, Travaglini D, et al. Neuropsychiatr Dis Treat. 2013;9:893-914.', '6.', 'Gasperini C, Ruggieri S, Mancinelli CR, et al. Advances in the treatment of relapsing-', 'remitting multiple sclerosis - critical appraisal of fingolimod. Ther Clin Risk Manag.', '2013;9 73-85.', '7.', 'Dhib-Jalbut S, Marks S. Interferon-beta mechanisms of action in multiple sclerosis.', 'Neurology 2010; 74(Suppl 1): S17-24.', '8.', 'Cree BAC. Multiple sclerosis. In: Brust JCM, ed. Current Diagnosis and Treatment in', 'Neurology. New York: Lange Medical Books/McGraw-Hil Medical; 2007.', '9.', 'PRISMS Study Group. Randomized double-blind placebo-controlled study of interferon', 'beta-la in relapsing/remitting multiple sclerosis. Lancet. 1998;352(9139):1498-504', '10. Li DK, Paty DW, PRISMS Study Group. Magnetic resonance imaging results of the', 'PRISMS study: A randomized, double-blind, placebo-controlled study of interferon beta-la', 'in relapsing-remitting multiple sclerosis. Ann Neurol. 1999;46(2) 197-206.', '11. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group.', 'PRISMS-4: Long-term efficacy of interferon beta-la in relapsing MS. Neurology', '2001;56(12):1628-36.', '12. SPECTRIMS Study Group, Hughes RAC. Randomized controlled study of interferon beta-', 'la in secondary progressive MS: Clinical results. Neurology. 2001;56(11):1496-504.', '13. Panitch H, Goodin D, Francis G, et al. Benefits of high-dose, high-frequency interferon', 'beta-la in relapsing-remitting multiple sclerosis are sustained to 16 months: final', 'comparative results of the EVIDENCE trial. J Neurol Sci. 2005;239(1):67-74', 'CONFIDENTIAL', '44/60', 'INFORMATION', 'VI']\n\n###\n\n", "completion": "END"}